Zyversa Therapeutics, INC 10-K annual reports
Annual reports — audited financials, the full risk-factor list, and management’s account of the year.
OQB
ZyVersa Therapeutics, a clinical-stage biopharmaceutical company, reported a significant net loss of $25.0 million in 2025, including an $18.6 million impairment charge, and was delisted from Nasdaq, raising substantial doubt about its going concern ability.
OQB
ZyVersa Therapeutics details its financial results for the year ended December 31, 2024, and outlines its strategic priorities for advancing its renal and inflammatory disease drug candidates.
OQB
10-K/A: ZyVersa Therapeutics Files Amendment to 2023 Annual Report, Addressing Internal Control Weaknesses
ZyVersa Therapeutics has filed an amendment to its 2023 annual report to clarify existing language and update the number of outstanding shares, while also addressing identified material weaknesses in internal controls.
OQB
ZyVersa Therapeutics' 10-K filing provides a detailed overview of its capital structure, including common and preferred stock, warrants, and anti-takeover provisions.